Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy

A Report from the SEARCH Database

Christopher R. King, Stephen J. Freedland, Martha Kennedy Terris, Christopher J. Kane, Christopher L. Amling, William J. Aronson, Joseph C. Presti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: To test the validity of preoperative prostate-specific antigen velocity (PSAV) (the rate of PSA rise before diagnosis) as a predictor for relapse after radical prostatectomy, in the context of patient obesity as measured by body mass index (BMI). Methods: The rates of biochemical relapse were examined among 215 patients who underwent radical prostatectomy between 1992 and 2005. Kaplan-Meier relapse rates as a function of preoperative PSAV 2 ng/mL/yr or less versus greater than 2 ng/mL/yr were compared in two groups: nonobese patients (normal to overweight, BMI less than 30 kg/m2) and obese patients (mild to severely obese, BMI 30 kg/m2 or greater). Results: A preoperative PSAV greater than 2 ng/mL/yr was associated with higher relapse rates after radical prostatectomy compared with a PSAV of 2 ng/mL/yr or less, with 5-year relapse-free survival rates of 60% versus 70%, respectively (P = 0.03). Prostate-specific antigen velocity was independently significant on multivariate analysis, along with biopsy Gleason score, percent positive cores, and BMI. In this study 24% of patients were obese. Prostate-specific antigen velocity greater than 2 ng/mL/yr was associated with higher relapse rates in nonobese patients (P = 0.01) but not in obese patients (P = 0.9). The two BMI groups did not differ with respect to any factors. Obese patients with slowly rising PSA (PSAV 2 ng/mL/yr or less) fared just as poorly as nonobese patients with rapidly rising PSA (PSAV greater than 2 ng/mL/yr). Obesity was independently associated with higher relapse rates. Conclusions: Preoperative PSAV greater than 2 ng/mL/yr was associated with a higher risk of relapse after radical prostatectomy, but its clinical usefulness might be limited to nonobese patients. Obesity conferred higher relapse rates, regardless of other prognostic factors including preoperative PSAV.

Original languageEnglish (US)
Pages (from-to)921-926
Number of pages6
JournalUrology
Volume69
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Obesity
Databases
Recurrence
Body Mass Index
Neoplasm Grading
Multivariate Analysis
Survival Rate
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy : A Report from the SEARCH Database. / King, Christopher R.; Freedland, Stephen J.; Terris, Martha Kennedy; Kane, Christopher J.; Amling, Christopher L.; Aronson, William J.; Presti, Joseph C.

In: Urology, Vol. 69, No. 5, 01.05.2007, p. 921-926.

Research output: Contribution to journalArticle

King, Christopher R. ; Freedland, Stephen J. ; Terris, Martha Kennedy ; Kane, Christopher J. ; Amling, Christopher L. ; Aronson, William J. ; Presti, Joseph C. / Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy : A Report from the SEARCH Database. In: Urology. 2007 ; Vol. 69, No. 5. pp. 921-926.
@article{94abecb4ab7340378aae61a84e186dc2,
title = "Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy: A Report from the SEARCH Database",
abstract = "Objectives: To test the validity of preoperative prostate-specific antigen velocity (PSAV) (the rate of PSA rise before diagnosis) as a predictor for relapse after radical prostatectomy, in the context of patient obesity as measured by body mass index (BMI). Methods: The rates of biochemical relapse were examined among 215 patients who underwent radical prostatectomy between 1992 and 2005. Kaplan-Meier relapse rates as a function of preoperative PSAV 2 ng/mL/yr or less versus greater than 2 ng/mL/yr were compared in two groups: nonobese patients (normal to overweight, BMI less than 30 kg/m2) and obese patients (mild to severely obese, BMI 30 kg/m2 or greater). Results: A preoperative PSAV greater than 2 ng/mL/yr was associated with higher relapse rates after radical prostatectomy compared with a PSAV of 2 ng/mL/yr or less, with 5-year relapse-free survival rates of 60{\%} versus 70{\%}, respectively (P = 0.03). Prostate-specific antigen velocity was independently significant on multivariate analysis, along with biopsy Gleason score, percent positive cores, and BMI. In this study 24{\%} of patients were obese. Prostate-specific antigen velocity greater than 2 ng/mL/yr was associated with higher relapse rates in nonobese patients (P = 0.01) but not in obese patients (P = 0.9). The two BMI groups did not differ with respect to any factors. Obese patients with slowly rising PSA (PSAV 2 ng/mL/yr or less) fared just as poorly as nonobese patients with rapidly rising PSA (PSAV greater than 2 ng/mL/yr). Obesity was independently associated with higher relapse rates. Conclusions: Preoperative PSAV greater than 2 ng/mL/yr was associated with a higher risk of relapse after radical prostatectomy, but its clinical usefulness might be limited to nonobese patients. Obesity conferred higher relapse rates, regardless of other prognostic factors including preoperative PSAV.",
author = "King, {Christopher R.} and Freedland, {Stephen J.} and Terris, {Martha Kennedy} and Kane, {Christopher J.} and Amling, {Christopher L.} and Aronson, {William J.} and Presti, {Joseph C.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1016/j.urology.2007.01.056",
language = "English (US)",
volume = "69",
pages = "921--926",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy

T2 - A Report from the SEARCH Database

AU - King, Christopher R.

AU - Freedland, Stephen J.

AU - Terris, Martha Kennedy

AU - Kane, Christopher J.

AU - Amling, Christopher L.

AU - Aronson, William J.

AU - Presti, Joseph C.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Objectives: To test the validity of preoperative prostate-specific antigen velocity (PSAV) (the rate of PSA rise before diagnosis) as a predictor for relapse after radical prostatectomy, in the context of patient obesity as measured by body mass index (BMI). Methods: The rates of biochemical relapse were examined among 215 patients who underwent radical prostatectomy between 1992 and 2005. Kaplan-Meier relapse rates as a function of preoperative PSAV 2 ng/mL/yr or less versus greater than 2 ng/mL/yr were compared in two groups: nonobese patients (normal to overweight, BMI less than 30 kg/m2) and obese patients (mild to severely obese, BMI 30 kg/m2 or greater). Results: A preoperative PSAV greater than 2 ng/mL/yr was associated with higher relapse rates after radical prostatectomy compared with a PSAV of 2 ng/mL/yr or less, with 5-year relapse-free survival rates of 60% versus 70%, respectively (P = 0.03). Prostate-specific antigen velocity was independently significant on multivariate analysis, along with biopsy Gleason score, percent positive cores, and BMI. In this study 24% of patients were obese. Prostate-specific antigen velocity greater than 2 ng/mL/yr was associated with higher relapse rates in nonobese patients (P = 0.01) but not in obese patients (P = 0.9). The two BMI groups did not differ with respect to any factors. Obese patients with slowly rising PSA (PSAV 2 ng/mL/yr or less) fared just as poorly as nonobese patients with rapidly rising PSA (PSAV greater than 2 ng/mL/yr). Obesity was independently associated with higher relapse rates. Conclusions: Preoperative PSAV greater than 2 ng/mL/yr was associated with a higher risk of relapse after radical prostatectomy, but its clinical usefulness might be limited to nonobese patients. Obesity conferred higher relapse rates, regardless of other prognostic factors including preoperative PSAV.

AB - Objectives: To test the validity of preoperative prostate-specific antigen velocity (PSAV) (the rate of PSA rise before diagnosis) as a predictor for relapse after radical prostatectomy, in the context of patient obesity as measured by body mass index (BMI). Methods: The rates of biochemical relapse were examined among 215 patients who underwent radical prostatectomy between 1992 and 2005. Kaplan-Meier relapse rates as a function of preoperative PSAV 2 ng/mL/yr or less versus greater than 2 ng/mL/yr were compared in two groups: nonobese patients (normal to overweight, BMI less than 30 kg/m2) and obese patients (mild to severely obese, BMI 30 kg/m2 or greater). Results: A preoperative PSAV greater than 2 ng/mL/yr was associated with higher relapse rates after radical prostatectomy compared with a PSAV of 2 ng/mL/yr or less, with 5-year relapse-free survival rates of 60% versus 70%, respectively (P = 0.03). Prostate-specific antigen velocity was independently significant on multivariate analysis, along with biopsy Gleason score, percent positive cores, and BMI. In this study 24% of patients were obese. Prostate-specific antigen velocity greater than 2 ng/mL/yr was associated with higher relapse rates in nonobese patients (P = 0.01) but not in obese patients (P = 0.9). The two BMI groups did not differ with respect to any factors. Obese patients with slowly rising PSA (PSAV 2 ng/mL/yr or less) fared just as poorly as nonobese patients with rapidly rising PSA (PSAV greater than 2 ng/mL/yr). Obesity was independently associated with higher relapse rates. Conclusions: Preoperative PSAV greater than 2 ng/mL/yr was associated with a higher risk of relapse after radical prostatectomy, but its clinical usefulness might be limited to nonobese patients. Obesity conferred higher relapse rates, regardless of other prognostic factors including preoperative PSAV.

UR - http://www.scopus.com/inward/record.url?scp=34247601513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247601513&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.01.056

DO - 10.1016/j.urology.2007.01.056

M3 - Article

VL - 69

SP - 921

EP - 926

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -